trending Market Intelligence /marketintelligence/en/news-insights/trending/tvm3ynqq-16jduulauwjka2 content esgSubNav
In This List

NYSE accepts CorMedix's plan to regain compliance with listing requirements

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


NYSE accepts CorMedix's plan to regain compliance with listing requirements

CorMedix Inc. said the New York Stock Exchange accepted its plan to regain compliance with its listing requirements.

The Brisbane, Calif.-based company had said in June that it received a noncompliance notice from the NYSE American.

The biopharmaceutical company had reported a stockholders' equity of $800,000, lower than a minimum of $2 million as required by NYSE.

CorMedix, which submitted its plan on July 16, has until Dec. 16, 2019 to regain compliance.